| Protocol | Title |
|---|---|
| 10403 | AN INTERGROUP PHASE II CLINICAL TRIAL FOR ADOLESCENTS AND YOUNG
ADULTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Activation Date: 14-may-2008 |
| 10404 | A Randomized Phase II Study of Three Fludarabine/Antibody
Combinations for Patients with Symptomatic Previously Untreated
Chronic Lymphocytic Leukemia
Activation Date: 14-may-2008 |
| CALGB10501 | A Phase III Intergroup CLL Study of Asymptomatic Patients with
Untreated Chronic Lymphocytic Leukemia Randomized To Early
Intervention Versus Observation with Later Treatment in the High risk
Genetic Subset with IGVh Unmutated Disease
Activation Date: 22-jan-2008 |
| E1900 | A Phase III Trial in Adult Acute Myeloid Leukemia:Daunorubicin
Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell
Transplantation
Activation Date: 16-dec-2002 |
| E1902 | A Phase II Study of Reduced Intensity Allogeneic Stem Cell Transplant
for the Treatment of Myelodysplastic Syndromes
Activation Date: 18-may-2005 ECOG Participants(requires Adobe Acrobat) |
| E1904 | A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase,
and Dexamethasone) with Subcutaneous Campath (NSC 715969) for Adults
with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)
Activation Date: 29-jun-2006 Suspended: 16-apr-2008 ECOG Participants(requires Adobe Acrobat) |
| E1905 | A Randomized Phase II Trial of Azacitidine with or without the
Histone Deacetylase Inhibitor MS-275 for the Treatment of
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic
type), and Acute Myeloid Leukemia with Multilineage Dysplasia
Activation Date: 18-aug-2006 |
| E2902 | A Phase III Randomized Study of Farnesyl Transferase Inhibitor
R115777 in Acute Myeloid Leukemia (AML) Patients in Second or
Subsequent Remission or Remission after Primary Induction Failure or
Patients over Age 60 in First Remission
Activation Date: 18-aug-2004 |
| E2903 | Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (PCR)
Followed By Campath-1H For Previously Treated Relapsed or Refractory
Patients With Chronic Lymphocytic Leukemia
Activation Date: 16-dec-2004 ECOG Participants(requires Adobe Acrobat) |
| E3903 | Ancillary laboratory protocol for collecting diagnostic material on
patients considered for ECOG treatment trials for leukemia or related
hematologic disorders
Activation Date: 08-jul-2004 ECOG Participants(requires Adobe Acrobat) |
| E5998 | A Phase II Study of Initial Treatment with Methotrexate in Large
Granular Lymphocytic (LGL) Leukemia
Activation Date: 16-jul-1999 ECOG Participants(requires Adobe Acrobat) |
| S0325 | A Phase IIb Study of Molecular Responses to Imatinib at Standard or
Increased, or Dasatinib (BMS 354825) (NSC 732517), for Previously
Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic
Phase.
Activation Date: 07-jan-2005 |
| S0521 | A Randomized Trial of Maintenance Versus Observation For Patients
With Previously Untreated Low and Intermediate Risk Acute Promyelomic
Leukemia (APL), Phase III
Activation Date: 22-jan-2008 |
| S0535 | A Phase II Study of ATRA, Arsenic Trioxide, and Gemtuzumab Ozogamicin
in Patients with Previously Untreated High-Risk Acute Promyelocytic
Leukemia
Activation Date: 23-jun-2008 |
All contents copyright © 1998 Eastern Cooperative Oncology Group.
All rights reserved.
Revised: 07/05/08